Navigation Links
Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
Date:5/22/2008

Presentation Will be Webcast Live and Archived on Company's Website

ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Vanda President and CEO will deliver a corporate presentation on Wednesday, May 28, 2008, at 9:00 a.m. Eastern Time.

The presentation will take place as part of the FBR Capital Markets 12th Annual Spring Investor Conference at the Grand Hyatt, New York, New York. Dr. Polymeropoulos' remarks will be available live on the Vanda Website, where it also will be archived for 30 days.

To access the presentation, log on to http://www.vandapharma.com and click on the Presentations option in the Investor Relations section. Please connect to the website several minutes prior to the start of the live presentation.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates. Vanda's lead product candidate, Fanapta(TM) (iloperidone), for which Vanda has recently submitted an NDA to the FDA, is a compound for the treatment of schizophrenia. Vanda's second product candidate, tasim
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Vanda Pharmaceuticals to Present at Natixis Bleichroeders Hidden Gems Conference
2. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
3. Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
4. Vanda Pharmaceuticals VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
5. Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... Floor:, Reduce Errors By 50% or More, **Presented by FDAnews and Ginette M. ... Ginette Collazo, a 15 year veteran of helping drug, biologic and device firms ...
(Date:7/30/2015)... ... , ... Committed to helping the next generation succeed - Mercy College is ... the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call to ... support they need to think more broadly about their future. Building on what works ...
(Date:7/30/2015)... ... 2015 , ... The Clinical Data Interchange Standards Consortium (CDISC), ... that data standards for clinical research in the areas of Schizophrenia, Hepatitis C ... These three Therapeutic Area (TA) standards were developed per the CDISC global, consensus-based ...
(Date:7/30/2015)... ... ... a healthy head of hair and a feeling of confidence is a powerful one for ... a devastating impact on the daily life of a person. From increased anxiety to ... loss are not to be taken lightly. , The skilled staff at Parsa Mohebi Hair ...
(Date:7/30/2015)... CATHERAL CITY, California (PRWEB) , ... July 30, 2015 , ... ... of substance abuse, clients at Serenity Palms Drug Addiction Treatment Center have created an ... Springs just lost one of its most beloved residents, Rocky Hudson . Hudson ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3
... Best Care Senior,Services has expanded into the Littleton/Denver, ... Service, and Personal,Response Company, is proud to announce ... Care Senior Services for outstanding care. For over ... of our work -- a,sincere concern for the ...
... Blood and Plasma Donor Centers, LENEXA, Kan., ... MEDW ), a provider of ClosedLoop(TM) clinical,systems for ... has,completed the acquisition of substantially all of the ... provider of software products and,services that enable blood ...
... Industry Sales Increase as Consumers Put Their Trust in Natural, Effective ... ... Oct. 31 There has been a profound shift in,the thinking ... become increasingly proactive in seeking more natural means to fight,sickness. As ...
... machinery in a cell to serve their own needs. According ... to gain access to that machinery. , A common target ... or pRb, which serves to block cell division when potentially ... of the retina, this tumor suppressor protein has since been ...
... if drug would have same benefit for Caucasians , , ... cancer with an experimental chemotherapy drug after surgery improved ... , The results of the trial won,t mean much ... S-1, is classified as "investigational" in the United States. ...
... The Medicare bidding,program for durable medical equipment will ... unless Congress modifies,the program. This is the key ... today by the American Association for Homecare.,The Association ... care, choice of provider, and access to the ...
Cached Medicine News:Health News:Announcing Always Best Care Senior Services Expansion Into the Littleton/Denver, Colorado Area 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 3Health News:Hyland's Inc. Reports More Consumers Turn to Homeopathic Medicines to Fight Illness at Home 2Health News:How one virus uses mimicry to replicate successfully 2Health News:Chemo Drug Improves Stomach Cancer Survival for Japanese Patients 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 3
(Date:7/30/2015)... July 30, 2015 What can ... Which areas are going to grow at the fastest ... potential revenues to 2025, assessing data, trends, opportunities and ... provides 176 tables, charts, and graphs. Discover the most ... prospects. Our new study lets you assess forecasted sales ...
(Date:7/30/2015)...  Lannett Company, Inc. (NYSE: LCI ) today ... Genuity 35th Annual Growth Conference on Wednesday, August 12, ... Hotel.  A webcast of the presentation ... encouraged to visit the web site at least 10 ... register, download and install any necessary software.  The presentation ...
(Date:7/30/2015)... 2015  Cleave Biosciences today announced that the ... the company a key patent providing the protection ... This newly issued patent, "Fused pyrimidines ... 9,062,026, allows for claims on the composition of ... inhibitor of p97, a critical enzyme that controls ...
Breaking Medicine Technology:Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... , SANTA ... nonpartisan 501(c)3 nonprofit public charity dedicated to promoting critical thinking, ... core question "Should any vaccines be required for children?" , ... certain vaccinations for children entering public schools. Depending on the ...
... ... Walking for People With All Types of Multiple Sclerosis , ... Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, ... to improve walking speed in people with any type of multiple ...
Cached Medicine Technology:Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 2Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
... System is the next generation ... the symptoms of BPH. This ... the prostate while dilating the ... well tolerated by patients and ...
... proud to announce the release of the OES ... optics with our most commonly used cystoscopy sheaths ... level. Now you can have one instrument that ... the OES Pro cystoscopes offer a superior channel ...
... Defibrillator is a simple "1, 2, ... is compact with a streamline design ... only 13.5 lbs. It rapidly charges ... has full summary pre- & post-event ...
Incontinence Pessaries...
Medicine Products: